ISA’s AMPLIVANT® technology comprises a proprietary and synthetic Toll-Like Receptor (TLR)1/2 ligand with enhanced immunostimulatory activity that can be coupled to the peptide in the standard SLP® manufacturing process. Long peptide-AMPLIVANT® conjugate immunotherapeutics allow lower dosing at higher efficacy through better dendritic cell antigen processing and presentation as well as enhanced T cell priming.
This technology is not only applicable to all SLP® immunotherapeutics, but also to any other type of targeted immunotherapy, and significantly enhances its efficacy.
Pre-clinical data demonstrate that conjugation of HPV-SLP® to AMPLIVANT® significantly potentiates anti-tumor immune responses. The safety and immunogenicity of ISA’s first SLP®-AMPLIVANT® conjugate ISA201 are currently investigated in collaboration with the LUMC (NL) in patients treated for HPV16-positive tumors or premalignant lesions.
ISA has entered a collaboration and license agreement with Scancell Ltd. (UK) to develop and commercialize AMPLIVANT® – Modi-1 conjugate therapy. Previous preclinical data demonstrate that conjugation of the citrullinated Modi-1 peptides to AMPLIVANT® enhances anti-tumor immune responses 10 to 100-fold and results in highly efficient tumor eradication, including protection against tumor re-challenge.
TLRs expressed by immune cells such as dendritic cells (DCs) or macrophages play a key role in innate immunity. They recognize characteristic molecular structures present on the surface of bacteria, called pathogen associated molecular patterns (PAMPs). Once these PAMPs bind to their receptors, a signaling cascade is triggered that, among others, leads to the activation of cells that initiate a potent acquired immune response.